Monopar Therapeutics | 8-K: FY2025 Q3 Revenue: USD 0

Revenue: As of FY2025 Q3, the actual value is USD 0.

EPS: As of FY2025 Q3, the actual value is USD -0.48, missing the estimate of USD -0.4346.

EBIT: As of FY2025 Q3, the actual value is USD -4.786 M.

Cash and Net Loss

• Cash, cash equivalents, and investments as of September 30, 2025, were $143.7 million. Monopar expects these funds to be sufficient to continue operations at least through December 31, 2027.
• Net loss for the third quarter of 2025 was $3.4 million or $0.48 per share, compared to a net loss of $1.3 million or $0.37 per share for the third quarter of 2024.

Research and Development (R&D) Expenses

• R&D expenses for the third quarter of 2025 were $2,589,749, compared to $984,278 for the third quarter of 2024, representing an increase of $1,605,471. This increase was due to a $937,582 rise in manufacturing activities related to ALXN1840, a $617,667 increase in R&D personnel expenses including stock-based compensation, and a net increase of $50,223 in other R&D expenses.

General and Administrative (G&A) Expenses

• G&A expenses for the third quarter of 2025 were $1,503,326, compared to $590,624 for the third quarter of 2024, marking an increase of $912,702. This was primarily due to a $369,959 increase in Board compensation from stock options granted in March 2025, a $287,749 increase in G&A personnel expenses including stock-based compensation, and a net increase of $254,993 in other G&A expenses.

Interest Income

• Interest income for the third quarter of 2025 increased by $556,129 compared to the same period in 2024, attributed to interest earned on U.S. Treasury securities and higher bank balances resulting from the approximately $91.9 million raised in the Offering after the Share Repurchase.

Outlook / Guidance

• Monopar is preparing to submit a New Drug Application (NDA) to the FDA for ALXN1840 in early 2026. The company expects its current funds to support operations through December 31, 2027, allowing for continued development of its pipeline, including MNPR-101-Zr and MNPR-101-Lu programs.